MilliporeSigma Wins CPhI Pharma Award for Excellence in Innovation

News
Article

The company was awarded for excellence in innovation for Parteck MXP Excipient and modified amino acids.

On Oct. 12, 2018, MilliporeSigma announced that it won two CPhI Pharma Awards for innovative products for the pharmaceutical industry. The awards were announced at CPhI’s award gala in Madrid, Spain.

“At MilliporeSigma, we provide innovations that help our customers advance science and accelerate access to better health for people everywhere,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma, in a company press release. “We are pleased that CPhI has recognized our commitment to drive the industry forward and empower researchers and scientists with products that improve drug development quality and efficiency.”

The company received the following awards:

  • Parteck MXP Excipient won for “Excellence in Excipients.” The product is a new polyvinyl alcohol excipient for the formulation of stable amorphous solid dispersions by hot melt extrusion. It offers enhanced API solubility and stable, high drug loads. The new excipient is applicable for a variety of final formulations with different release kinetics and offers the formulator flexibility in designing a drug product that fits the respective API and desired therapeutic effect.

  • MilliporeSigma’s modified amino acids won for “Excellence in Bioprocessing and Manufacturing.” The modified amino acids Phospho-Tyrosine disodium salt and Sulfo-Cysteine sodium salt are components for biomanufacturing and mAb processes, designed to simplify fed-batch processes in applying a single-feed strategy.

The CPhI Pharma Awards celebrate thinkers and creators breaking new ground in the industry and advocate companies that are committed to driving the industry forward. CPhI Wordwide was held in Madrid on Oct. 9–11, 2018.

Source: MilliporeSigma

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content